PTJ
NDRM

Paul Tudor Jones’s NeuroDerm Ltd. Ordinary Shares NDRM Stock Holding History

Paul Tudor Jones’s Portfolio NDRM Stock Details NDRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-10,000
Closed -$222K – 1679
2016
Q4 		$222K Buy
+10,000
New +$187K 0.01% 1173

Other funds holding NDRM

SCM
Scopia Capital Management New York $112M AUM 48.41% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $143M AUM 102.52% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $143M AUM 773.18% 1-Year Est. Return
SAM
Senzar Asset Management New York $34.7M AUM 0.56% 1-Year Est. Return

Paul Tudor Jones's NDRM Position: Q1 2017 in Review

Paul Tudor Jones sold out of NeuroDerm Ltd. Ordinary Shares (NDRM) in Q1 2017, closing a stake of 10,000 shares — an estimated $222K sold.

Paul Tudor Jones first reported a position in NDRM in Q4 2016 and held it in 1 quarter. The position peaked at $222K in Q4 2016. 70 funds tracked by Wall St. Rank hold NDRM as of Q1 2017.

  • Paul Tudor Jones reported no remaining NeuroDerm Ltd. Ordinary Shares position as of Q1 2017 after selling out during the quarter.
  • Paul Tudor Jones sold 10,000 NeuroDerm Ltd. Ordinary Shares shares in Q1 2017, an estimated $222K.
  • Paul Tudor Jones first reported a position in NeuroDerm Ltd. Ordinary Shares in Q4 2016 and held it in 1 quarter.
  • Paul Tudor Jones's NeuroDerm Ltd. Ordinary Shares position peaked at $222K in Q4 2016.
  • 70 funds tracked by Wall St. Rank held NeuroDerm Ltd. Ordinary Shares as of Q1 2017.

Based on Tudor Investment Corp's 13F filing for Q1 2017, filed 15 May 2017.